Patents by Inventor Dieter Zopf

Dieter Zopf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer
    Patent number: 11951166
    Abstract: The present invention relates to pharmaceutical compositions and combinations comprising regorafenib or its hydrate, solvate, metabolite or pharmaceutically acceptable salt or a polymorph thereof and a PD-1/PD-L1(2) inhibitor for treating, preventing or managing diseases and conditions including hyperproliferative disorders such as cancer in humans and other mammals.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: April 9, 2024
    Assignee: BAYER AKTIENGESELLSCHAFT
    Inventors: Sabine Hoff, Lars Rose, Dieter Zopf, Fabian Kiessling, Wiltrud Lederle, Dennis Doleschel
  • Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer
    Patent number: 11517622
    Abstract: The present invention relates to pharmaceutical compositions and combinations comprising regorafenib or its hydrate, solvate, metabolite or pharmaceutically acceptable salt or a polymorph thereof and a PD-1/PD-L1(2) inhibitor for treating, preventing or managing diseases and conditions including hyperproliferative disorders such as cancer in humans and other mammals.
    Type: Grant
    Filed: December 31, 2019
    Date of Patent: December 6, 2022
    Assignee: BAYER HEALTHCARE LLC
    Inventors: Sabine Hoff, Lars Rose, Dieter Zopf, Fabian Kiessling, Wiltrud Lederle, Dennis Doleschel
  • COMBINATION OF REGORAFENIB AND PD-1/PD-L1(2) INHIBITORS FOR TREATING CANCER
    Publication number: 20220133888
    Abstract: The present invention relates to pharmaceutical compositions and combinations comprising regorafenib or its hydrate, solvate, metabolite or pharmaceutically acceptable salt or a polymorph thereof and a PD-1/PD-L1(2) inhibitor for treating, preventing or managing diseases and conditions including hyperproliferative disorders such as cancer in humans and other mammals.
    Type: Application
    Filed: January 14, 2022
    Publication date: May 5, 2022
    Applicant: BAYER AKTIENGESELLSCHAFT
    Inventors: Sabine HOFF, Lars RÖSE, Dieter ZOPF, Fabian KIESSLING, Wiltrud LEDERLE, Dennis DOLESCHEL
  • COMBINATION OF REGORAFENIB AND PD-1/PD-L1(2) INHIBITORS FOR TREATING CANCER
    Publication number: 20200188372
    Abstract: The present invention relates to pharmaceutical compositions and combinations comprising regorafenib or its hydrate, solvate, metabolite or pharmaceutically acceptable salt or a polymorph thereof and a PD-1/PD-L1(2) inhibitor for treating, preventing or managing diseases and conditions including hyperproliferative disorders such as cancer in humans and other mammals.
    Type: Application
    Filed: December 31, 2019
    Publication date: June 18, 2020
    Applicant: BAYER AKTIENGESELLSCHAFT
    Inventors: Sabine HOFF, Lars ROSE, Dieter ZOPF, Fabian KIESSLING, Wiltrud LEDERLE, Dennis DOLESCHEL
  • COMBINATION OF REGORAFENIB AND PD-1/PD-L1(2) INHIBITORS FOR TREATING CANCER
    Publication number: 20200179354
    Abstract: The present invention relates to pharmaceutical compositions and combinations comprising regorafenib or its hydrate, solvate, metabolite or pharmaceutically acceptable salt or a polymorph thereof and a PD-1/PD-L1(2) inhibitor for treating, preventing or managing diseases and conditions including hyperproliferative disorders such as cancer in humans and other mammals.
    Type: Application
    Filed: May 25, 2018
    Publication date: June 11, 2020
    Applicant: BAYER AKTIENGESELLSCHAFT
    Inventors: Sabine HOFF, Lars ROSE, Dieter ZOPF, Fabian KIESSLING, Wiltrud LEDERLE, Dennis DOLESCHEL
  • COMBINATION OF REGORAFENIB AND PD-1/PD-L1(2) INHIBITORS FOR TREATING CANCER
    Publication number: 20200155674
    Abstract: The present invention relates to pharmaceutical compositions and combinations comprising regorafenib or its hydrate, solvate, metabolite or pharmaceutically acceptable salt or a polymorph thereof and a PD-1/PD-L1(2) inhibitor for treating, preventing or managing diseases and conditions including hyperproliferative disorders such as cancer in humans and other mammals.
    Type: Application
    Filed: December 31, 2019
    Publication date: May 21, 2020
    Applicant: BAYER AKTIENGESELLSCHAFT
    Inventors: Sabine HOFF, Lars ROSE, Dieter ZOPF, Fabian KIESSLING, Wiltrud LEDERLE, Dennis DOLESCHEL
  • Sulphoximine-substituted quinoline and quinazoline derivatives as kinase inhibitors
    Patent number: 8003787
    Abstract: The present invention relates to a quinoline or quinazoline derivative having the general formula (A): in which R3, R4, W, Y and Q are indicated in the description and the claims, the use of the compounds of the general formula (A) for the treatment of various disorders, and the preparation of compounds of the general formula (A).
    Type: Grant
    Filed: May 23, 2008
    Date of Patent: August 23, 2011
    Assignee: Bayer Schering Pharma AG
    Inventors: Knut Eis, Olaf Prien, Ulrich Lücking, Judith Günther, Dieter Zopf, Dirk Brohm, Verena Vöhringer, Elisabeth Woltering, Hartmut Beck, Mario Lobell, Volkhart Min-Jian Li, Susanne Greschat
  • 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents
    Patent number: 7977325
    Abstract: This invention relates to compounds of general formula I in which R1 and R2 are described in this application, the use of the compounds of general formula I as inhibitors of protein tyrosine kinases for treatment of various diseases as well as the compounds of general formulas II and III as intermediate compounds for the production of compounds of general formula I, wherein X, R1a and R2a have the meaning that is described in general formulas II and III.
    Type: Grant
    Filed: December 14, 2005
    Date of Patent: July 12, 2011
    Assignee: Bayer Schering Pharma AG
    Inventors: Wolfgang Schwede, Hermann Kuenzer, Antonius Ter Laak, Benjamin Bader, Roman Hillig, Ursula Moenning, Arndt Schmitz, Dieter Zopf
  • Quinazoline derivatives, their preparation, their use, and medicaments comprising them
    Patent number: 7741333
    Abstract: The present invention relates to a quinazoline derivative having the general formula (A): in which R1, R2, X, Y and Z are indicated in the description and the claims, the use of the compounds of the general formula (A) for the treatment of various disorders, and the preparation of compounds of the general formula (A).
    Type: Grant
    Filed: June 21, 2007
    Date of Patent: June 22, 2010
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Olaf Prien, Knut Eis, Wolfgang Schwede, Judith Guenther, Dieter Zopf, Dominic E. A. Brittain
  • Anti-androgenic pyrrolidines with tumor-inhibiting action
    Patent number: 7601748
    Abstract: This invention relates to anti-androgenic N-[?-[3-[4-cyano-3-(trifluoromethyl)-phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]alkyl]-substituted pyrrolidines of general formula I, with a strongly pronounced antiproliferative profile of action; process for the production of the compounds of general formula I, pharmaceutical preparations and the use for the production of pharmaceutical agents.
    Type: Grant
    Filed: August 9, 2006
    Date of Patent: October 13, 2009
    Assignee: Bayer Schering Pharma AG
    Inventors: Arwed Cleve, Volker Schulze, Dieter Zopf, Jens Hoffmann, Andreas Reichel, Karsten Parczyk
  • Cyanoquinoline derivatives, their preparation, their use, and medicaments comprising them
    Patent number: 7598263
    Abstract: The present invention relates to a quinoline derivative having the general formula (A): in which R1, R2, X, Y and Z are indicated in the description and the claims, the use of the compounds of the general formula (A) for the treatment of various disorders, and the preparation of compounds of the general formula (A).
    Type: Grant
    Filed: June 20, 2007
    Date of Patent: October 6, 2009
    Assignee: Bayer Schering Pharma AG
    Inventors: Olaf Prien, Knut Eis, Wolfgang Schwede, Judith Guenther, Dieter Zopf
  • NOVEL SULPHOXIMINE-SUBSTITUTED QUINOLINE AND QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS
    Publication number: 20090226377
    Abstract: The present invention relates to a quinoline or quinazoline derivative having the general formula (A): in which R3, R4, W, Y and Q are indicated in the description and the claims, the use of the compounds of the general formula (A) for the treatment of various disorders, and the preparation of compounds of the general formula (A).
    Type: Application
    Filed: May 23, 2008
    Publication date: September 10, 2009
    Inventors: Knut EIS, Olaf Prien, Ulrich Lucking, Judith Gunther, Dieter Zopf, Dirk Brohm, Verena Vohringer, Elisabeth Woltering, Hartmut Beck, Mario Lobell, Volkhart Min-Jian Li, Susanne Greschat
  • ANTI EPHB4 ANTIBODIES AND ANTIBODY FRAGMENTS
    Publication number: 20090137002
    Abstract: The invention concerns antibodies and antibody fragments, specifically recognising the EphB4 receptor comprising heavy chains and light chain, comprising light and heavy CDR's, and their use as medicament for the treatment of pathological angiogenesis, in particular cancer therapy.
    Type: Application
    Filed: July 30, 2008
    Publication date: May 28, 2009
    Inventors: Heike PETRUL, Andreas Menrad, Jorg Willuda, Dieter Zopf, Jens Glienke, Josef Prassler, Andreas Popp, Stefan Steidl, Catrin Pracht
  • High affinity human and humanized anti-alpha5beta1 integrin function blocking antibodies with reduced immunogenicity
    Publication number: 20090081207
    Abstract: The present invention relates to recombinant human or humanized polypeptides which bind to ?5?1 integrin with high affinity and blocking function. Further, diagnostic and pharmaceutic applications of the potypeptides are disclosed.
    Type: Application
    Filed: May 23, 2007
    Publication date: March 26, 2009
    Inventors: ANDREAS MENRAD, JOERG WILLUDA, KLAUS BOSSLET, DIETER ZOPF, HEIKE PETRUL, STEFAN STEIDL, JOSEF PRASSLER, CORINNE PETIT-FRERE
  • 3-Amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents
    Publication number: 20090030010
    Abstract: This invention relates to compounds of general formula I in which R1 and R2 are described in this application, the use of the compounds of general formula I as inhibitors of protein tyrosine kinases for treatment of various diseases as well as the compounds of general formulas II and III as intermediate compounds for the production of compounds of general formula I, whereby X, R1a and R2a have the meaning that is described in general formulas II and III.
    Type: Application
    Filed: December 14, 2005
    Publication date: January 29, 2009
    Inventors: Wolfgang Schwede, Hermann Kuenzer, Antonius Ter Laak, Benjamin Bader, Roman Hillig, Ursula Moenning, Arndt Schmitz, Dieter Zopf
  • CYANOQUINOLINE DERIVATIVES, THEIR PREPARATION, THEIR USE, AND MEDICAMENTS COMPRISING THEM
    Publication number: 20080108627
    Abstract: The present invention relates to a quinoline derivative having the general formula (A): in which R1, R2, X, Y and Z are indicated in the description and the claims, the use of the compounds of the general formula (A) for the treatment of various disorders, and the preparation of compounds of the general formula (A).
    Type: Application
    Filed: June 20, 2007
    Publication date: May 8, 2008
    Inventors: Olaf Prien, Knut Eis, Wolfgang Schwede, Judith Guenther, Dieter Zopf
  • Androgenic 7-substituted 11-halogen steroids
    Patent number: 7361645
    Abstract: The invention relates to 11?-halogen steroids with general formula (I), whereby R11 is halogen, X—Y-Z represents a group with one of the two structures CH?C—C or CH2—C?C and the other radicals have the meaning that is indicated in the claims, also the production and use of these compounds for the production of pharmaceutical agents as well as pharmaceutical preparations that contain 11?-halogen steroids.
    Type: Grant
    Filed: January 24, 2002
    Date of Patent: April 22, 2008
    Assignee: Bayer Schering Pharma AG
    Inventors: Rolf Bohlmann, Hermann Kuenzer, Reinhard Nubbemeyer, Dieter Zopf
  • Quinoline derivatives, their preparation, their use, and medicaments comprising them
    Publication number: 20080056987
    Abstract: The present invention relates to a quinoline derivative having the general formula (A) in which R1, R2, W, X, Y and Z are indicated in the description and the claims, the use of the compounds of the general formula (A) for the treatment of various disorders, and the preparation of compounds of the general formula (A).
    Type: Application
    Filed: June 20, 2007
    Publication date: March 6, 2008
    Inventors: Olaf Prien, Knut Eis, Duy Nguyen, Christoph Huwe, Wolfgang Schwede, Judith Guenther, Dieter Zopf
  • QUINAZOLINE DERIVATIVES, THEIR PREPARATION, THEIR USE, AND MEDICAMENTS COMPRISING THEM
    Publication number: 20080019922
    Abstract: The present invention relates to a quinazoline derivative having the general formula (A): in which R1, R2, X, Y and Z are indicated in the description and the claims, the use of the compounds of the general formula (A) for the treatment of various disorders, and the preparation of compounds of the general formula (A).
    Type: Application
    Filed: June 21, 2007
    Publication date: January 24, 2008
    Inventors: Olaf Prien, Knut Eis, Wolfgang Schwede, Judith Guenther, Dieter Zopf, Dominic Brittain
  • Anti-androgenic pyrrolidines with tumor-inhibiting action
    Publication number: 20070021481
    Abstract: This invention relates to anti-androgenic N-[?-[3-[4-cyano-3-(trifluoromethyl)-phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]alkyl]-substituted pyrrolidines of general formula I, with a strongly pronounced antiproliferative profile of action; process for the production of the compounds of general formula I, pharmaceutical preparations and the use for the production of pharmaceutical agents.
    Type: Application
    Filed: August 9, 2006
    Publication date: January 25, 2007
    Inventors: Arwed Cleve, Volker Schulze, Dieter Zopf, Jens Hoffmann, Andreas Reichel, Karsten Parczyk